Page 41 - T Cell News Today

Researchers report humoral T-cell responses in seronegative MS patients after receiving a third COVID-19 booster vaccine dose.

A Phase I/Ib trial conducted by the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group NRG Oncology, NRG-GY017, concluded that the addition of the immunotherapy drug atezolizumab prior to and concurrently given with chemoradiation (CRT) treatment was safe for women with node-positive, locally advanced cervical cancer.

Scientists evaluate the humoral and cellular immune responses in individuals who have received a third booster dose of mRNA-based COVID-19 vaccine.

Researchers evaluated biomarkers that could help identify COVID-19 patients needing invasive mechanical ventilation.

The study reports that people who have been vaccinated or exposed to infection have some level of protection against Omicron.

A team of scientists has found a new type of human T cell that stops attacks on healthy issues, and this could lead to novel treatments for cancer.

Advanced Therapy Medicinal Product classification for Ixaka Ltd’s chemically encapsulated lentiviral vector - News - PharmaTimes

A new paper explores the presence of CD4 T-cell-mediated adaptive immunity against SARS-CoV-2 in late convalescence.

Researchers at the University of Michigan Rogel Cancer Center found that a cytokine, a category of protein that acts as messengers in the body, and a fatty acid can work together to trigger a type of cell death previously defined by studies with synthetic molecules.

Jeff Dontz, chair of the Manistee County Board of Commissioners, has reached five years...